Measuring patient and clinician perspectives to evaluate change in health-related quality of life among patients with chronic obstructive pulmonary disease

Journal of General Internal Medicine

Volumn 22, Issue 2, 2007, Pages 161-170

  Wyrwich, Kathleen W ^a,b   Metz, Stacie M ^c   Kroenke, Kurt ^d,e   Tierney, William M ^d,e   Babu, Ajit N ^f,g   Wolinsky, Fredric D ^b,h,i  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c WEST CHESTER UNIVERSITY   (United States)

^d Regrenstrief Inst for Health Care   (United States)

^e INDIANA UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^h UNIVERSITY OF IOWA   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; Health related quality of life; Minimal important difference

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHYSICIAN; PRIMARY MEDICAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; SELF EVALUATION; SHORT FORM 36; SYMPTOM; TRIANGULATION; COMPARATIVE STUDY; EVALUATION; GENERAL PRACTITIONER; HEALTH SURVEY; MIDDLE AGED; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; STANDARD;

AGED; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHYSICIANS, FAMILY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 34250328811     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-006-0063-6     Document Type: Article

References (33)

1. Food and Drug Administration. Innovation or Stagnation: Challenges And Opportunities on the Critical Path to New Medical Products. Washington, DC: US Department of Health and Human Services; March 2004.
2. Schunemann H, Guyatt GH. Commentary-goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res. 2005;40(2):593.
3. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407-15.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.com; October 26, 2001.
5. Guyatt G, Berman L, Townsend M, Pugsley S, Chambers L. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773-8.
6. Ware J, Kosinski M, Dewey J. How to Score Version Two of the SF-36 Health Survey. Lincoln, RI: QualityMetric Inc.; 2000.
7. Lacasse Y, Wong E, Guyatt G. A systematic overview of the measurement properties of the chronic respiratory questionnaire. Can Respir J. 1997;4(3):131-9.
8. Schunemann H, Griffith L, Jaeschke R, et al. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest. 2003;124(4):1421-9.
9. Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52(9):861-73.
10. Brazier J, Harper R, Jones N. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J. 1992;305:160-4.
11. Patrick D, Deyo R. Generic and disease-specific measures in assessing quality of life. Med Care. 1989;27:S217-32.
12. Wyrwich K, Fihn S, Tierney W, Kroenke K, Babu A, Wolinsky F. Clinically important differences in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert panel report. J Gen Intern Med. 2003;18(3):196-202.
13. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11:207-21.
14. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005;40(2):577-92.
15. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Respir J. 2003;21:36S-45S.
16. Webster GD. Final Report of the ABIM Patient Satisfaction Project. Philadelphia: American Board of Internal Medicine; 1988.
17. McHorney CA, Lerner J. The 1990 NORC National Health Survey: Documentation and Codebook. Chicago: National Opinion Research Council; 1991.
18. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705-14.
19. Mirowsky J, Ross CE. Eliminating defense and agreement bias from measures of the sense of control: a 2×2 index. Soc Psychol Q. 1991;54:127-45.
20. Fetzer Institute. Multidimensional Measurement of Religiousness/ Spirituality for Use in Health Research. Kalamazoo: John E. Fetzer Institute; 1999.
21. Juniper E, Guyatt G, Willan A, Griffith L. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-7.
22. Statistical Package for the Social Sciences. SPSS for Windows, release 13.0.0. Chicago: SPSS, Inc.; 2005.
23. Streiner D, Norman G. Reliability. In: Health Measurement Scales, 3rd edn., Chap. 8. Oxford: Oxford University Press; 2003.
24. Jones G, Jenkinson C, Kennedy S. Evaluating the responsiveness of the endometriosis health profile questionnaire: the EHP-30. Qual Life Res. 2004;13:705-13.
25. Singh S, Sodergren S, Hyland M, Williams J, Morgan M. A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Respir Med. 2001;95:71-7.
26. Juniper E, Price D, Stampone P, Creemers J, Mol S, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest. 2002;121:1824-32.
27. Chauhan C, Eppard W, Perroti J. The patient advocate perspective on assessing the clinical significance for quality-of-life measures. J Cancer Integr Med. 2004;2(4):155-7.
28. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomised trials? J Clin Epidemiol. 1994;47:787-95.
29. Norman G, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: the lessons of Cronbach. J Clin Epidemiol. 1997;50(8):869-79.
30. Guyatt G, Norman G, et al. A critical look at transition ratings. J Clin Epidemiol. 2002;55:900-8.
31. Stratford P, Binkley J, Solomon P, et al. Defining the minimal level of detectable change for the Roland Morris Questionnaire. Phys Ther. 1996;76:359-65.
32. Schwartz C, Sprangers M. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48:1531-48.
33. Pulmonary Allergy Drugs Advisory Committee. New Drug Application (NDA) 21-395, Spiriva (Tiotropium bromide). Gaithersburg, MD: Food and Drug Administration; 2002.